'Cancer Rates and Risks' Available

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 11
Volume 5
Issue 11

BETHESDA, Md--The National Cancer Institute has released the latest edition of Cancer Rates and Risks, a 205-page reference book with cancer statistics and brief chapters by NCI experts, written in lay language, on known cancer risk factors. Single copies are available free through the NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).

BETHESDA, Md--The National Cancer Institute has released the latest edition of Cancer Rates and Risks, a 205-page reference book with cancer statistics and brief chapters by NCI experts, written in lay language, on known cancer risk factors. Single copies are available free through the NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).

Articles in this issue
Factor Analysis of New Symptom Scale in Breast Cancer Finds Six Clusters
AIDS Funding Increased for Fiscal '97
'Cancer Rates and Risks' Available
New Breast Cancer Patient Resource Is Available
Short-Term Metronidazole not Linked to Cancer
Various Capitation Models Are Available for Oncology Networks
NCI Urges full Disclosure of Cigarette Contents
Antifungal Resistance on the Increase
Fentanyl Patch Useful Alternative in Cancer Pain Patients
Analysis of Microvessel Density Predicts Extraprostatic Spread
Late Infection With Cytomegalovirus a Serious Problem in Bone Marrow Transplant Patients
FDA Panel Cancels HIV Drug Meeting
Klausner Cites Breast Cancer Progress in Jo Oberstar Lecture
Foundation Supports Legislation Backing Cancer Treatment Coverage
FDA Approves Xillix LIFE-Lung System
Recent Videos
HIPEC/CRS Confers No Benefit, Adds Risk in Colorectal Peritoneal Metastases
HIPEC/CRS Confers No Benefit, Adds Risk in Colorectal Peritoneal Metastases
The Importance of Multidisciplinary Care in Bone Marrow Transplantation
The Importance of Multidisciplinary Care in Bone Marrow Transplantation
Providing easier access to ancillary services for patients with PDAC who live farther away from the treatment center may help them complete the treatment regimen.
Ensuring Ancillary Care Access to Bolster QOL in Pancreatic Cancer
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
PIPAC-MMC Shows Efficacy in Multiple Response Criteria for Peritoneal Mets
Immunotherapy Plus Transplantation Improves Outcomes in Relapsed Lymphoma
Immunotherapy Plus Transplantation Improves Outcomes in Relapsed Lymphoma
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Peritoneal Tumor Treatment Enhanced by Pre-PIPAC-MMC Small Incision Surgery
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Intraperitoneal Therapy Seeks to Address “Nihilism” Around Peritoneal Mets
Greater cancer treatment longevity enables oncologists the ability to form more impactful relationships with their patients.
Theranostics and Radiopharmaceutical Use May Enhance Cancer Care
Episode 4: Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer
Episode 4: Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer
3 experts are featured in this series.
Second-Line Treatment for Gastric Adenocarcinoma
Related Content
Telehealth Groups May Improve the Social Lives of Young Cancer Populations

Telehealth Groups May Improve the Social Lives of Young Cancer Populations

Tim Cortese
April 3rd 2025
Article

Most patients with cancer who took part in a telehealth group expressed that they liked the members of their group and felt less social isolation.

Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
April 1st 2025
Podcast

A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.

Data from the phase 3 CheckMate 77T trial support the CHMP’s opinion on approving the perioperative nivolumab regimen for those with resectable NSCLC.

EU’s CHMP Recommends Approving Perioperative Nivolumab Combo in NSCLC

Russ Conroy
April 2nd 2025
Article

Data from the phase 3 CheckMate 77T trial support the CHMP’s opinion on approving the perioperative nivolumab regimen for those with resectable NSCLC.

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

Improving NSCLC Surgery Recovery After Climate Disaster Exposure

Leticia Nogueira, PhD, MPH
March 31st 2025
Podcast

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

A Staged Approach Offers Benefits Without OS Detriment in Appendix Cancers

A Staged Approach Offers Benefits Without OS Detriment in Appendix Cancers

Tim Cortese
April 2nd 2025
Article

Muhammad Talwa Waheed, MD, found that resection after appendectomy should be prioritized in the treatment of patients with appendiceal cancer.

The phase 3 ROSELLA trial results assessing relacorliant/nab-paclitaxel in patients with platinum-resistant ovarian cancer will support an upcoming NDA.

Relacorilant/Chemo Show Survival Benefit in Platinum-Resistant Ovarian Cancer

Roman Fabbricatore
April 2nd 2025
Article

The phase 3 ROSELLA trial results assessing relacorliant/nab-paclitaxel in patients with platinum-resistant ovarian cancer will support an upcoming NDA.